Health and Healthcare
Stock Gains Skipping Biotech (GENZ, CELG, GILD, AMGN, BIIB, ALXN, MNKD, HGSI, VVUS, DNDN, BBH, XBI, QQQQ)
Published:
Last Updated:
Biotech and emerging pharma both seem to have almost no friends today despite a large stock market rally. It may take a resolution of the Genzyme Corporation (NASDAQ: GENZ) merger, and a successful resolution at that, to get interest going in the sector in. We have run a feature at BioHealthInvestor.com showing how many key biotech stocks are being left in the dust despite the improvement from tax extensions, QE2, the move to risk-assets, and general economic improvements.
Those issues covered are Celgene Corporation (NASDAQ: CELG), Gilead Sciences Inc. (NASDAQ: GILD), Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), MannKind Corp. (NASDAQ: MNKD), Human Genome Sciences Inc. (NASDAQ: HGSI), VIVUS Inc. (NASDAQ: VVUS), and Dendreon Corporation (NASDAQ: DNDN)… most of which were flops this last week while the NASDAQ and the broader stocks performed well. We also compared the Biotech HOLDRs (NYSE: BBH) and SPDR S&P Biotech (NYSE: XBI) to the PowerShares QQQ (NASDAQ: QQQQ) to highlight some of the underperformance.
Read the full report at BioHealthInvestor.com
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
